Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (July 2015). "Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature". Clinical Pharmacokinetics. 54 (7): 709–35. doi:10.1007/s40262-015-0267-1. PMID25860377. S2CID35961181.
Ferreira RJ, Ferreira MJ, Dos Santos DJ (June 2012). "Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations". Journal of Chemical Theory and Computation. 8 (6): 1853–64. doi:10.1021/ct300083m. PMID26593820.
Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Advanced Drug Delivery Reviews. 36 (2–3): 179–194. doi:10.1016/S0169-409X(98)00085-4. PMID10837715.
Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. (September 2010). "Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma". Digestive Diseases and Sciences. 55 (9): 2545–51. doi:10.1007/s10620-009-1051-6. PMID19960259. S2CID43382510.
Ruike Z, Junhua C, Wenxing P (November 2010). "In vitro and in vivo evaluation of the effects of duloxetine on P-gp function". Human Psychopharmacology. 25 (7–8): 553–559. doi:10.1002/hup.1152. PMID21312289. S2CID3516785.
van Assema DM, van Berckel BN (2016). "Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?". Current Pharmaceutical Design. 22 (38): 5808–5816. doi:10.2174/1381612822666160804094544. PMID27494062.
Wilk JN, Bilsborough J, Viney JL (2005). "The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease". Immunologic Research. 31 (2): 151–9. doi:10.1385/ir:31:2:151. PMID15778512. S2CID21256040.
Breier A, Gibalova L, Seres M, Barancik M, Sulova Z (January 2013). "New insight into p-glycoprotein as a drug target". Anti-Cancer Agents in Medicinal Chemistry. 13 (1): 159–70. doi:10.2174/1871520611307010159. PMID22931413.
Juliano RL, Ling V (November 1976). "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants". Biochimica et Biophysica Acta (BBA) - Biomembranes. 455 (1): 152–62. doi:10.1016/0005-2736(76)90160-7. PMID990323.
Luurtsema G, Windhorst AD, Mooijer MP, Herscheid A, Lammertsma AA, Franssen EJ (2002). "Fully automated high yield synthesis of (R)- and (S)-[C-11]verapamil for measuring P-glycoprotein function with positron emission tomography". Journal of Labelled Compounds and Radiopharmaceuticals. 45 (14): 1199–1207. doi:10.1002/jlcr.632.
Wirths S, Lanzavecchia A (December 2005). "ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells". European Journal of Immunology. 35 (12): 3433–41. doi:10.1002/eji.200535364. PMID16259010. S2CID24412083.
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (July 2015). "Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature". Clinical Pharmacokinetics. 54 (7): 709–35. doi:10.1007/s40262-015-0267-1. PMID25860377. S2CID35961181.
Ferreira RJ, Ferreira MJ, Dos Santos DJ (June 2012). "Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations". Journal of Chemical Theory and Computation. 8 (6): 1853–64. doi:10.1021/ct300083m. PMID26593820.
Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood-brain barrier". Advanced Drug Delivery Reviews. 36 (2–3): 179–194. doi:10.1016/S0169-409X(98)00085-4. PMID10837715.
Yang JM, Vassil AD, Hait WN (October 2001). "Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway". Molecular Pharmacology. 60 (4): 674–80. PMID11562428.
Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. (September 2010). "Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma". Digestive Diseases and Sciences. 55 (9): 2545–51. doi:10.1007/s10620-009-1051-6. PMID19960259. S2CID43382510.
Ruike Z, Junhua C, Wenxing P (November 2010). "In vitro and in vivo evaluation of the effects of duloxetine on P-gp function". Human Psychopharmacology. 25 (7–8): 553–559. doi:10.1002/hup.1152. PMID21312289. S2CID3516785.
van Assema DM, van Berckel BN (2016). "Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?". Current Pharmaceutical Design. 22 (38): 5808–5816. doi:10.2174/1381612822666160804094544. PMID27494062.
Wilk JN, Bilsborough J, Viney JL (2005). "The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease". Immunologic Research. 31 (2): 151–9. doi:10.1385/ir:31:2:151. PMID15778512. S2CID21256040.
Breier A, Gibalova L, Seres M, Barancik M, Sulova Z (January 2013). "New insight into p-glycoprotein as a drug target". Anti-Cancer Agents in Medicinal Chemistry. 13 (1): 159–70. doi:10.2174/1871520611307010159. PMID22931413.
Juliano RL, Ling V (November 1976). "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants". Biochimica et Biophysica Acta (BBA) - Biomembranes. 455 (1): 152–62. doi:10.1016/0005-2736(76)90160-7. PMID990323.
Wirths S, Lanzavecchia A (December 2005). "ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells". European Journal of Immunology. 35 (12): 3433–41. doi:10.1002/eji.200535364. PMID16259010. S2CID24412083.
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (July 2015). "Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature". Clinical Pharmacokinetics. 54 (7): 709–35. doi:10.1007/s40262-015-0267-1. PMID25860377. S2CID35961181.
Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. (April 1997). "Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression". Nature Medicine. 3 (4): 447–50. doi:10.1038/nm0497-447. PMID9095180. S2CID13323149.
Bark H, Choi CH (May 2010). "PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB". Cancer Chemotherapy and Pharmacology. 65 (6): 1131–6. doi:10.1007/s00280-009-1121-7. PMID19763573. S2CID31179492.
Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. (September 2010). "Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma". Digestive Diseases and Sciences. 55 (9): 2545–51. doi:10.1007/s10620-009-1051-6. PMID19960259. S2CID43382510.
Ruike Z, Junhua C, Wenxing P (November 2010). "In vitro and in vivo evaluation of the effects of duloxetine on P-gp function". Human Psychopharmacology. 25 (7–8): 553–559. doi:10.1002/hup.1152. PMID21312289. S2CID3516785.
Wilk JN, Bilsborough J, Viney JL (2005). "The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease". Immunologic Research. 31 (2): 151–9. doi:10.1385/ir:31:2:151. PMID15778512. S2CID21256040.
Wirths S, Lanzavecchia A (December 2005). "ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells". European Journal of Immunology. 35 (12): 3433–41. doi:10.1002/eji.200535364. PMID16259010. S2CID24412083.